Scarica l'app Stockscreener
3.14
0.32%
-0.010
Dopo l'orario di chiusura:
3.14
Precedente Chiudi:
$3.15
Aprire:
$3.13
Volume 24 ore:
9,097
Relative Volume:
0.79
Capitalizzazione di mercato:
$42.76M
Reddito:
-
Utile/perdita netta:
$-10.54M
Rapporto P/E:
-1.3888
EPS:
-2.261
Flusso di cassa netto:
$-7.21M
1 W Prestazione:
-1.88%
1M Prestazione:
-7.65%
6M Prestazione:
-35.79%
1 anno Prestazione:
+49.52%
Intervallo 1D:
$3.0562
$3.15
Intervallo di 1 settimana:
$2.8001
$3.3985
Portata 52W:
$2.07
$11.44
Intensity Therapeutics Inc Stock (INTS) Company Profile
Nome
Intensity Therapeutics Inc
Settore
Industria
Telefono
203-221-7381
Indirizzo
1 ENTERPRISE DRIVE, SUITE 430, SHELTON
Confronta INTS con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
| INTS | 3.14 | 42.76M | 0 | -10.54M | -7.21M | -2.261 |
| VRTX | 467.01 | 119.87B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 762.00 | 83.27B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 567.90 | 33.96B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 232.27 | 30.18B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 101.87 | 24.42B | 3.30B | -501.07M | 1.03B | 11.54 |
Intensity Therapeutics Inc Borsa (INTS) Ultime notizie
Intensity reports promising sarcoma treatment results - Investing.com
Intensity Therapeutics' Cancer Drug Triples Survival Time in Phase 1/2 Sarcoma Trial | INTS Stock News - StockTitan
Q&A: New cancer medication to treat refractory solid tumours - Digital Journal
Intensity Therapeutics Reports Wider Q3 Loss, Advances Key Cancer Drug Trials | INTS Stock News - StockTitan
3 US Penny Stocks With Market Caps Under $200M To Watch - Simply Wall St
Intensity Therapeutics Selected for Oral Podium Presentation in a Late-Breaking Session at the 2024 Annual Connective Tissue Oncology Society (Sarcomas) Meeting - The Malaysian Reserve
Intensity Therapeutics, Inc. and The Swiss Group for Clinical Cancer Research SAKK Announce the First Patient Dosed in the Randomized, Presurgical Triple Negative Breast Cancer Phase 2 Clinical Trial (INVINCIBLE-4 / SAKK 66/22) - Quantisnow
TScan Therapeutics Announces Upcoming Oral Presentation of Data from the ALLOHA™ Phase 1 Heme Trial at the 66th American Society of Hematology Annual Meeting and Exposition - The Manila Times
TScan Therapeutics Announces Upcoming Oral Presentation of - GlobeNewswire
INTSIntensity Therapeutics, Inc. Latest Stock News & Market Updates - StockTitan
This Alumis Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday - Benzinga
Balancing Decisions Around Breast Cancer Treatment and Fertility, Breastfeeding - Curetoday.com
New Data Demonstrates Long-Term Improvements in Pain Intensity with Nevro's High-Frequency Spinal Cord Stimulation Therapy - Yahoo Finance
Intensity Therapeutics grants stock options to top executives By Investing.com - Investing.com South Africa
Intensity Therapeutics grants stock options to top executives - Investing.com
High-intensity, low-impact training (HILIT) is gentle on joints and can boost your metabolism. Here’s how to get started - Yahoo Finance
Biliary Tumor Pipeline Therapeutics, Assessment, Companies, Products, Unmet Needs, Market Drivers and Barriers - Barchart
SONIRE’s HIFU Therapy System Designated as Breakthrough Device by FDA - BioSpace
SONIRE's HIFU Therapy System Designated as Breakthrough Device by FDA - The Manila Times
Cholangiocarcinoma Pipeline Therapeutics, Assessment, Companies, Products, Unmet Needs, Market Drivers and Barriers - The Globe and Mail
Thoracic Re-irradiation With Definitive External Beam Radiation Therapy Using Intensity Modulated Radiation Therapy: A Case Report - Cureus
Herceptin, Perjeta Regimen May Be Effective Without Chemo in Breast Cancer - Curetoday.com
Side Effects, Quality of Life Important to Consider in Breast Cancer Subset - Curetoday.com
There is Nothing Pink About Breast Cancer - Curetoday.com
Head and Neck Cancer Therapeutics Market Overview: Breakthrough Treatments, Technological Innovations, and ... - WhaTech
An Analysis of Ideaya Biosciences Inc (IDYA)’s Potential Price Growth - Knox Daily
Weekly Investment Analysts’ Ratings Changes for Incyte (INCY) - Defense World
Inogen: Upside Seems Limited After Big Move Up (NASDAQ:INGN) - Seeking Alpha
InvenTrust Properties (NYSE:IVT) Sees Strong Trading Volume - Defense World
Skandinaviska Enskilda Banken AB publ Increases Position in Itron, Inc. (NASDAQ:ITRI) - Defense World
Ideaya Biosciences price target lowered to $52 from $54 at Wedbush - TipRanks
Hoosier Hysterics Podcast: Sisley commits, plus IUWBBs Shay Ciezki and Karoline Striplin - 247Sports
Ideaya Biosciences should be bought on weakness, says Citi - TipRanks
Intapp, Inc. (NASDAQ:INTA) Shares Sold by Hood River Capital Management LLC - MarketBeat
(TIL) Long Term Investment Analysis - Stock Traders Daily
Low-intensity pulsed ultrasound modulates disease progression in the SOD1 - ScienceDirect.com
Itim Group PLC Announces Strong Mid-Year Financials - TipRanks
ITT Educational Services (OTCMKTS:ESINQ) Stock Price Passes Above Two Hundred Day Moving Average of $0.00 - Defense World
InvenTrust Properties Corp. Announces Upsizing and Pricing of Common Stock Offering - StockTitan
We Think Shareholders Are Less Likely To Approve A Large Pay Rise For Intense Technologies Limited's (NSE:INTENTECH) CEO For Now - Simply Wall St
US FDA Closes Out Problem Applications One Federal Register Notice At A Time - Pink Sheet
Ideaya Biosciences price target lowered to $66 from $68 at Stifel - TipRanks
BTIG maintains $62 target on Ideaya Biosciences stock - Investing.com
From Statins to PSCK9 Inhibitors: Choosing the Right Therapy for Cholesterol - Pharmacy Times
Intercontinental Exchange, Inc. (NYSE:ICE) Shares Sold by Interval Partners LP - Defense World
ILLIT Comeback 'I'll Like You' Mini-Album: Release Date, Tracklist - J-14
Integra Lifesciences Holdings Corp (IART) Becoming More Attractive for Investors - Knox Daily
Itau Unibanco Holding S.A. Acquires New Position in Incyte Co. (NASDAQ:INCY) - Defense World
ILLIT Announce First Comeback With Upcoming Mini-Album ‘I’LL LIKE YOU’ - Billboard Philippines
ILLIT announces 2nd mini-album I'LL LIKE YOU, set for October 21 release, marking comeback 7 months after debut - PINKVILLA
ILLIT flaunts 'candid charm' in upcoming EP 'I'll Like You' - ABS-CBN News
Intensity Therapeutics Inc Azioni (INTS) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
3.66%
1.11%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):